Page 18 - BH-3-3

Brain & Heart Advances in stroke treatment

5. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy acute middle cerebral artery stroke. PROACT Investigators.
6 to 24 hours after stroke with a mismatch between deficit Prolyse in acute cerebral thromboembolism. Stroke.
and infarct. N Engl J Med. 2018;378(1):11-21. 1998;29(1):4-11.
doi: 10.1056/NEJMoa1706442 doi: 10.1161/01.str.29.1.4
6. Haley EC Jr., Thompson JL, Grotta JC, et al., Phase IIB/III 15. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial
trial of tenecteplase in acute ischemic stroke: Results of a prourokinase for acute ischemic stroke. The PROACT II
prematurely terminated randomized clinical trial. Stroke. study: A randomized controlled trial. Prolyse in acute cerebral
2010;41(4):707-711. thromboembolism. JAMA. 1999;282(21):2003-2011.
doi: 10.1161/STROKEAHA.109.572040 doi: 10.1001/jama.282.21.2003
7. Parsons M, Spratt N, Bivard A, et al. A randomized trial 16. Li S, Gu HQ, Feng B, et al. Safety and efficacy of intravenous
of tenecteplase versus alteplase for acute ischemic stroke. recombinant human prourokinase for acute ischaemic stroke
N Engl J Med. 2012;366(12):1099-1107. within 4·5 h after stroke onset (PROST-2): A phase 3, open-
doi: 10.1056/NEJMoa1109842 label, non-inferiority, randomised controlled trial. Lancet
Neurol. 2025;24(1):33-41.
8. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus
tenecteplase for thrombolysis after ischaemic stroke doi: 10.1016/S1474-4422(24)00436-8
(ATTEST): A phase 2, randomised, open-label, blinded 17. Xiong Y, Hao M, Pan Y, et al. Rationale and design of
endpoint study. Lancet Neurol. 2015;14(4):368-376. ProUrokinase in Mild IsChemic strokE (PUMICE):
A multicentre, prospective, randomised, open-label,
doi: 10.1016/S1474-4422(15)70017-7
blinded-endpoint controlled trial. Stroke Vasc Neurol.
9. Campbell BC, Mitchell PJ, Churilov L, et al. Tenecteplase 2024;9(6):715-722.
versus alteplase before endovascular thrombectomy
(EXTEND-IA TNK): A multicenter, randomized, controlled doi: 10.1136/svn-2023-002673
study. Int J Stroke. 2018;13(3):328-334. 18. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized
doi: 10.1177/1747493017733935 trial of intraarterial treatment for acute ischemic stroke.
N Engl J Med. 2015;372(1):11-20.
10. Xiong Y, Campbell BCV, Fisher M, et al. Rationale and design
of tenecteplase reperfusion therapy in acute ischaemic doi: 10.1056/NEJMoa1411587
cerebrovascular Events III (TRACE III): A randomised, 19. Liu X, Dai Q, Ye R, et al. Endovascular treatment versus
phase III, open-label, controlled trial. Stroke Vasc Neurol. standard medical treatment for vertebrobasilar artery
2024;9(1):82-89. occlusion (BEST): An open-label, randomised controlled
doi: 10.1136/svn-2023-002310 trial. Lancet Neurol. 2020;19(2):115-122.
11. Bivard A, Zhao H, Churilov L, et al. Comparison of doi: 10.1016/S1474-4422(19)30395-3
tenecteplase with alteplase for the early treatment of 20. Drumm B, Banerjee S, Qureshi MM, et al. Current opinions
ischaemic stroke in the melbourne mobile stroke unit on optimal management of basilar artery occlusion: After
(TASTE-A): A phase 2, randomised, open-label trial. Lancet the BEST of BASICS survey. Stroke Vasc Intervent Neurol.
Neurol. 2022;21(6):520-527. 2022;2:e000538.
doi: 10.1016/S1474-4422(22)00171-5 doi: 10.1161/SVIN.122.000538
12. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase 21. Edwards C, Drumm B, Siegler JE, et al. Basilar artery
compared with alteplase for acute ischaemic stroke in occlusion management: Specialist perspectives from an
Canada (AcT): A pragmatic, multicentre, open-label, international survey. J Neuroimaging. 2023;33:422-433.
registry-linked, randomised, controlled, non-inferiority
trial. Lancet. 2022;400(10347):161-169. doi: 10.1111/jon.13084
22. Tao C, Nogueira RG, Zhu Y, et al. Trial of endovascular
doi: 10.1016/S0140-6736(22)01054-6
treatment of acute basilar-artery occlusion. N Engl J Med.
13. Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus 2022;387(15):1361-1372.
alteplase for management of acute ischaemic stroke (NOR-
TEST): A phase 3, randomised, open-label, blinded endpoint doi: 10.1056/NEJMoa2206317
trial. Lancet Neurol. 2017;16(10):781-788. 23. Jovin TG, Li C, Wu L, et al. Trial of thrombectomy 6 to 24
hours after stroke due to basilar-artery occlusion. N Engl J
doi: 10.1016/S1474-4422(17)30253-3
Med. 2022;387(15):1373-1384.
14. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS,
Rowley HA, Gent M. PROACT: A phase II randomized trial doi: 10.1056/NEJMoa2207576
of recombinant pro-urokinase by direct arterial delivery in 24. Yoshimura S, Sakai N, Yamagami H, et al. Endovascular

Volume 3 Issue 3 (2025) 10 doi: 10.36922/bh.6683